PRESS IN THE NEWS March 3 2020 EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance February 11 2020 EpicentRx opens clinical site at Utah Cancer Specialists for RRx-001 in Small Cell Lung Cancer December 4 2019 EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer November 25, 2019 EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma November 13, 2019 EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform November 05, 2019 EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer June 25, 2019 EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC) May 02, 2018 First Patient Treated With Next-Generation Immunotherapy at UC Cincinnati May 02, 2018 EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines August 19, 2015 EpicentRx Announces Publication of Phase 1 Trial Results for the Anti-Cancer Agent, RRx-001, in Lancet Oncology August 09, 2018 Radioprotectors: Defensive Weapons In The War On Cancer
